Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2627) 2627
Publication (201) 201
Book Review (60) 60
Newsletter (37) 37
Magazine Article (17) 17
Book Chapter (14) 14
Newspaper Article (10) 10
Conference Proceeding (6) 6
Trade Publication Article (2) 2
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
glatiramer acetate (2458) 2458
humans (1748) 1748
multiple sclerosis (1646) 1646
index medicus (1125) 1125
clinical neurology (948) 948
multiple sclerosis - drug therapy (838) 838
female (835) 835
peptides - therapeutic use (748) 748
neurosciences (697) 697
male (665) 665
adult (660) 660
double-blind (583) 583
immunosuppressive agents - therapeutic use (536) 536
animals (501) 501
interferon-beta - therapeutic use (490) 490
multiple sclerosis, relapsing-remitting - drug therapy (452) 452
middle aged (450) 450
neurology (394) 394
placebo-controlled trial (389) 389
experimental autoimmune encephalomyelitis (387) 387
treatment outcome (366) 366
immunology (364) 364
multiple sclerosis - immunology (325) 325
pharmacology & pharmacy (324) 324
interferon-beta (323) 323
interferon beta-1a (315) 315
multiple-sclerosis (308) 308
immunologic factors - therapeutic use (292) 292
disability (289) 289
natalizumab (284) 284
magnetic resonance imaging (277) 277
disease progression (273) 273
multicenter (271) 271
adjuvants, immunologic - therapeutic use (257) 257
drug therapy (253) 253
central-nervous-system (251) 251
interferon beta-1b (251) 251
myelin basic-protein (233) 233
therapy (230) 230
mice (229) 229
care and treatment (225) 225
interferon (220) 220
research (217) 217
interferon beta (216) 216
experimental allergic encephalomyelitis (203) 203
peptides - administration & dosage (194) 194
peptides - pharmacology (194) 194
analysis (192) 192
copolymer 1 (191) 191
medicine & public health (186) 186
peptides - adverse effects (186) 186
multiple sclerosis - therapy (183) 183
t-cells (181) 181
multiple sclerosis - pathology (171) 171
disease (161) 161
health aspects (160) 160
immunosuppressive agents - adverse effects (156) 156
fingolimod (153) 153
immunosuppressive agents - administration & dosage (152) 152
young adult (152) 152
psychiatry (150) 150
multiple sclerosis - physiopathology (149) 149
glatiramer acetate - therapeutic use (146) 146
time factors (146) 146
multiple sclerosis - diagnosis (139) 139
recurrence (139) 139
inflammation (137) 137
adolescent (135) 135
medicine, general & internal (133) 133
disability evaluation (132) 132
relapse rate (132) 132
copaxone (127) 127
immunosuppressive agents - pharmacology (126) 126
immunotherapy (123) 123
neuroprotection (123) 123
t cells (122) 122
remitting multiple-sclerosis (121) 121
brain - pathology (119) 119
clinical trials as topic (119) 119
retrospective studies (118) 118
biological response modifiers (113) 113
disease models, animal (113) 113
progressive multifocal leukoencephalopathy (113) 113
t-lymphocytes - immunology (110) 110
encephalomyelitis, autoimmune, experimental - immunology (109) 109
interferon-beta - administration & dosage (108) 108
mri (107) 107
clinical trials (106) 106
encephalomyelitis, autoimmune, experimental - drug therapy (106) 106
immunomodulation (106) 106
mice, inbred c57bl (106) 106
regulatory t-cells (106) 106
autoimmunity (105) 105
cytokines (105) 105
diagnostic-criteria (103) 103
disease-activity (103) 103
dosage and administration (103) 103
dendritic cells (102) 102
multiple sclerosis, relapsing-remitting - immunology (100) 100
development and progression (99) 99
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2429) 2429
German (70) 70
Spanish (63) 63
Russian (56) 56
French (20) 20
Hungarian (13) 13
Japanese (13) 13
Czech (10) 10
Polish (6) 6
Portuguese (6) 6
Finnish (5) 5
Chinese (4) 4
Italian (4) 4
Serbian (2) 2
Turkish (2) 2
Dutch (1) 1
Hebrew (1) 1
Korean (1) 1
Norwegian (1) 1
Slovak (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
by Mikol, Daniel D, MD and Barkhof, Frederik, MD and Chang, Peter, PhD and Coyle, Patricia K, MD and Jeffery, Douglas R, MD and Schwid, Steven R, MD and Stubinski, Bettina, MD and Uitdehaag, Bernard MJ, MD and REGARD Study Grp and REGARD study group
Lancet Neurology, ISSN 1474-4422, 2008, Volume 7, Issue 10, pp. 903 - 914
Summary Background Interferon beta-1a and glatiramer acetate are commonly prescribed for relapsing-remitting multiple sclerosis (RRMS), but no published... 
Neurology | DEPRESSION | BENEFIT | GUIDELINES | DOUBLE-BLIND | DISABILITY | SECONDARY PROGRESSIVE MS | BETA-1A | PLACEBO-CONTROLLED TRIAL | DIAGNOSTIC-CRITERIA | COPOLYMER-1 | CLINICAL NEUROLOGY | Disability Evaluation | Interferon-beta - administration & dosage | Multiple Sclerosis, Relapsing-Remitting - pathology | Confidence Intervals | Drug Administration Schedule | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Humans | Middle Aged | Immunologic Factors - administration & dosage | Glatiramer Acetate | Magnetic Resonance Imaging - methods | Male | Treatment Outcome | Disease Progression | Peptides - administration & dosage | Injections, Subcutaneous - methods | Interferon beta-1a | Adolescent | Adult | Female | Retrospective Studies | Medical research | Multiple sclerosis | Care and treatment | Interferon beta | Medicine, Experimental | Comparative analysis | Biological response modifiers | Acetates | Drugs | Subpopulations | Magnetic resonance imaging | Motivation | copolymer 1 | Clinical trials | Interferon
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial
by Cohen, Jeffrey and Belova, Anna and Selmaj, Krzysztof and Wolf, Christian and Sormani, Maria Pia and Oberyé, Janine and van den Tweel, Evelyn and Mulder, Roel and Koper, Norbert and Voortman, Gerrit and Barkhof, Frederik and Glatiramer Acetate Clin Trial and Glatiramer Acetate Clinical Trial to Assess Equivalence With Copaxone (GATE) Study Group and for the Glatiramer Acetate Clinical Trial to Assess Equivalence With Copaxone (GATE) Study Group
JAMA Neurology, ISSN 2168-6149, 12/2015, Volume 72, Issue 12, pp. 1433 - 1441
IMPORTANCE: The patents for the first approved treatments for relapsing-remitting multiple sclerosis are expiring, creating the opportunity to develop generic... 
RELAPSES | MULTICENTER | SURROGATE | EFFICACY | SAFETY | TOLERABILITY | DOUBLE-BLIND | DISABILITY | OPEN-LABEL | CLINICAL NEUROLOGY | DISEASE-ACTIVITY | Disability Evaluation | Double-Blind Method | Follow-Up Studies | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Treatment Outcome | Young Adult | Magnetic Resonance Imaging | Time Factors | Glatiramer Acetate - therapeutic use | Injections, Subcutaneous | Adolescent | Adult | Female | Multiple Sclerosis - drug therapy | Therapeutic Equivalency
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Three times weekly glatiramer acetate in relapsing–remitting multiple sclerosis
by Khan, Omar and Rieckmann, Peter and Boyko, Alexey and Selmaj, Krzysztof and Zivadinov, Robert and GALA Study Grp and GALA Study Group
Annals of Neurology, ISSN 0364-5134, 06/2013, Volume 73, Issue 6, pp. 705 - 713
Objective To assess the efficacy and safety of glatiramer acetate (GA) 40mg administered 3× weekly (tiw) compared with placebo in patients with... 
TRIAL | PILOT | MULTICENTER | MECHANISM | DOUBLE-BLIND | DISABILITY | INJECTIONS | NEUROSCIENCES | CLINICAL NEUROLOGY | Prospective Studies | Double-Blind Method | Drug Administration Schedule | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Humans | Middle Aged | Glatiramer Acetate | Male | Treatment Outcome | Peptides - administration & dosage | Multiple Sclerosis, Relapsing-Remitting - epidemiology | Adult | Female | Immunosuppressive Agents - administration & dosage
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Randomized study combining interferon and glatiramer acetate in multiple sclerosis
by Lublin, Fred D and Cofield, Stacey S and Cutter, Gary R and Conwit, Robin and Narayana, Ponnada A and Nelson, Flavia and Salter, Amber R and Gustafson, Tarah and Wolinsky, Jerry S and CombiRx Investigators
Annals of Neurology, ISSN 0364-5134, 03/2013, Volume 73, Issue 3, pp. 327 - 340
Objective A double‐blind, randomized, controlled study was undertaken to determine whether combined use of interferon β‐1a (IFN) 30μg intramuscularly weekly... 
TRIAL | BRAIN ATROPHY | MRI | DISEASE | VOLUME | SEGMENTATION | MECHANISMS | THERAPIES | NEUROSCIENCES | CLINICAL NEUROLOGY | Disability Evaluation | Double-Blind Method | Humans | Middle Aged | Glatiramer Acetate | Male | Treatment Outcome | Secondary Prevention | Case-Control Studies | Interferon-beta - therapeutic use | Young Adult | Magnetic Resonance Imaging | Analysis of Variance | Adolescent | Adult | Female | Retrospective Studies | Drug Therapy, Combination | Longitudinal Studies | Peptides - therapeutic use | Immunologic Factors - therapeutic use | Multiple Sclerosis - drug therapy | Clinical trials | Multiple sclerosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing–remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study
by Khan, Omar and Rieckmann, Peter and Boyko, Alexey and Selmaj, Krzysztof and Ashtamker, Natalia and Davis, Mat D and Kolodny, Scott and Zivadinov, Robert
Multiple Sclerosis Journal, ISSN 1352-4585, 5/2017, Volume 23, Issue 6, pp. 818 - 829
Background: The 1-year placebo-controlled (PC) phase of the Glatiramer Acetate Low-Frequency Administration (GALA) study showed that glatiramer acetate 40... 
Glatiramer acetate | low-frequency regimen | annualized relapse rate | safety | relapsing-remitting multiple sclerosis | MULTICENTER | ACCURATE | GRAY | ATROPHY ASSESSMENT | NEUROSCIENCES | ADHERENCE | CLINICAL NEUROLOGY | THERAPY | ROBUST | DOUBLE-BLIND | DISABILITY | Glatiramer Acetate - pharmacology | Recurrence | Double-Blind Method | Follow-Up Studies | Outcome Assessment (Health Care) | Glatiramer Acetate - administration & dosage | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Humans | Middle Aged | Male | Multiple Sclerosis, Relapsing-Remitting - physiopathology | Disease Progression | Magnetic Resonance Imaging | Glatiramer Acetate - adverse effects | Multiple Sclerosis, Relapsing-Remitting - diagnostic imaging | Adult | Female | Immunosuppressive Agents - adverse effects | Immunosuppressive Agents - pharmacology | Immunosuppressive Agents - administration & dosage | Drugs | Neuroimaging | Multiple sclerosis | Copolymer 1 | Nuclear magnetic resonance--NMR | Magnetic resonance imaging | Gadolinium | Interferon | Substantia grisea
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Glatiramer Acetate in the Treatment of Multiple Sclerosis
: Emerging Concepts Regarding its Mechanism of Action
by Lalive, Patrice H and Neuhaus, Oliver and Benkhoucha, Mahdia and Burger, Danielle and Hohlfeld, Reinhard and Zamvil, Scott S and Weber, Martin S
CNS Drugs, ISSN 1172-7047, 5/2011, Volume 25, Issue 5, pp. 401 - 414
Glatiramer acetate is a synthetic, random copolymer widely used as a first-line agent for the treatment of relapsing-remitting multiple sclerosis (MS). While... 
Pharmacotherapy | Neurology | Neurosciences | Medicine & Public Health | Psychiatry | Psychopharmacology | Glatiramer-acetate, pharmacodynamics | Immunomodulators, pharmacodynamics | Multiple-sclerosis | EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS | DENDRITIC CELLS | PSYCHIATRY | EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS | COPOLYMER 1 | CLINICAL NEUROLOGY | MYELIN BASIC-PROTEIN | IL-1 RECEPTOR ANTAGONIST | TRANSCRIPTION FACTOR FOXP3 | REGULATORY T-CELLS | PHARMACOLOGY & PHARMACY | CENTRAL-NERVOUS-SYSTEM | PLACEBO-CONTROLLED TRIAL | Multiple Sclerosis, Relapsing-Remitting - immunology | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Encephalomyelitis, Autoimmune, Experimental - drug therapy | Humans | Encephalomyelitis, Autoimmune, Experimental - immunology | Glatiramer Acetate | Male | Peptides - pharmacology | Animals | Neuroprotective Agents - pharmacology | Multiple Sclerosis - immunology | Female | Mice | Immunosuppressive Agents - pharmacology | Disease Models, Animal | Multiple Sclerosis - drug therapy | Glatiramer acetate | Multiple sclerosis | Antigen presenting cells | Physiological aspects | Research | Drug therapy | Health aspects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Glatiramer acetate for multiple sclerosis
by La Mantia, Loredana and Munari, Luca M and Lovati, Roberta
Cochrane database of systematic reviews (Online), ISSN 1469-493X, 2010, Volume 5, Issue 5, pp. CD004678 - CD004678
Background This is an updated Cochrane review of the previous version published (Cochrane Database of Systematic Reviews 2004, Issue 1. Art. No.: CD004678.... 
LONG-TERM | Multiple Sclerosis, Relapsing-Remitting [drug therapy] | IMMUNOMODULATORY TREATMENT | Humans | Treatment Outcome | LOCALIZED LIPOATROPHY | Immunosuppressive Agents [therapeutic use] | Peptides [therapeutic use] | OPEN-LABEL | INTERFERON-BETA | Randomized Controlled Trials as Topic | DISEASE-ACTIVITY | Multiple Sclerosis, Chronic Progressive [drug therapy] | MEDICINE, GENERAL & INTERNAL | IMMUNE-RESPONSES | DOUBLE-BLIND | TERM-FOLLOW-UP | RELAPSING-REMITTING MS | Recurrence | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Immunosuppressive Agents - therapeutic use | Glatiramer Acetate | Multiple Sclerosis, Chronic Progressive - drug therapy | Disease Progression | Peptides - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Glatiramer Acetate
: Evidence for a dual mechanism of action
by Blanchette, François and Neuhaus, Oliver
Journal of Neurology, ISSN 0340-5354, 3/2008, Volume 255, Issue S1, pp. 26 - 36
Glatiramer acetate is a disease-modifying drug approved for the treatment of relapsing-remitting multiple sclerosis. Since its discovery almost four decades... 
Glatiramer acetate | Neurology | Neurosciences | Medicine & Public Health | T-cell | inflammation | multiple sclerosis | neuroprotection | Neuroradiology | Neuroprotection | Multiple sclerosis | Inflammation | EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS | RELAPSE RATE | NEUROTROPHIC FACTOR | HLA-DR MOLECULES | COPOLYMER 1 | glatiramer acetate | CLINICAL NEUROLOGY | MYELIN BASIC-PROTEIN | REMITTING MULTIPLE-SCLEROSIS | MAGNETIC-RESONANCE-SPECTROSCOPY | DOUBLE-BLIND | T-CELL LINES | Adjuvants, Immunologic - pharmacology | History, 21st Century | History, 20th Century | Humans | Adjuvants, Immunologic - history | Glatiramer Acetate | Th2 Cells - drug effects | Peptides - history | Peptides - pharmacology | Polysaccharides - metabolism | Animals | Adjuvants, Immunologic - therapeutic use | Peptides - therapeutic use | Multiple Sclerosis - drug therapy | Usage | Research | Drug therapy | T cells | Health aspects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Two decades of subcutaneous glatiramer acetate injection: Current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing-remitting multiple sclerosis treatment
by Caporro, Matteo and Disanto, Giulio and Gobbi, Claudio and Zecca, Chiara
Patient Preference and Adherence, ISSN 1177-889X, 08/2014, Volume 8, pp. 1123 - 1134
Glatiramer acetate, a synthetic amino acid polymer analog of myelin basic protein, is one of the first approved drugs for the treatment of relapsing-remitting... 
Glatiramer acetate | Efficacy | Disease modifying treatment | Safety | CONTROLLED PHASE-3 | MULTICENTER | COPOLYMER 1 | INTERFERON-BETA | glatiramer acetate | efficacy | ORAL BG-12 | MEDICINE, GENERAL & INTERNAL | disease modifying treatment | safety | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | DISEASE-MODIFYING THERAPIES | PROSPECTIVE OPEN-LABEL | Multiple sclerosis | Relapse | Dosage and administration | Drug therapy | Diseases | Antigens | Neurosciences | Nuclear magnetic resonance--NMR | Cytokines | Pathogenesis | Amino acids | Pregnancy | Lymphocytes | Interferon | Drug dosages | Binding sites | Pharmaceuticals
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Effect of switching from glatiramer acetate 20 mg/daily to glatiramer acetate 40 mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis: A longitudinal DTI study
by Zivadinov, Robert and Bergsland, Niels and Hagemeier, Jesper and Tavazzi, Eleonora and Ramasamy, Deepa P and Durfee, Jackie and Cherneva, Mariya and Carl, Ellen and Carl, Jillian and Kolb, Channa and Hojnacki, David and Weinstock-Guttman, Bianca
Journal of the Neurological Sciences, ISSN 0022-510X, 04/2018, Volume 387, pp. 152 - 156
Glatiramer acetate (GA) 40 mg × 3/weekly was approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). While the beneficial effect of GA... 
Glatiramer acetate | DTI | Multiple sclerosis | Tract based spatial statistics | MRI | ACCURATE | MECHANISM | ATROPHY | NEUROSCIENCES | BLACK-HOLES | LESIONS | CLINICAL NEUROLOGY | TRIAL | ROBUST | REGISTRATION | BRAIN | Medicine, Experimental | Medical research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Glatiramer acetate: A complex drug beyond biologics
by Rocco, Paolo and Eberini, Ivano and Musazzi, Umberto M and Franzè, Silvia and Minghetti, Paola
European Journal of Pharmaceutical Sciences, ISSN 0928-0987, 05/2019, Volume 133, pp. 8 - 14
Complex drugs may be either biological, if the active ingredients are derived from a biological source, or non-biological, if obtained by chemical synthesis.... 
NBCD | Complex drug | Glatiramer | Glatiramoid | MULTICENTER | MULTIPLE-SCLEROSIS | SAFETY | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | EQUIVALENCE | Glatiramer acetate | Generic drugs | Independent regulatory commissions | Chemical synthesis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial
by Comi, G, Prof and Martinelli, V, MD and Rodegher, M, MD and Moiola, L, MD and Bajenaru, O, Prof and Carra, A, Prof and Elovaara, I, Prof and Fazekas, F, Prof and Hartung, HP, Prof and Hillert, J, Prof and King, J, MD and Komoly, S, Prof and Lubetzki, C, Prof and Montalban, X, Prof and Myhr, KM, Prof and Ravnborg, M, MD and Rieckmann, P, Prof and Wynn, D, MD and Young, C, Prof and Filippi, M, MD and PreCISe Study Grp and PreCISe study group
Lancet, The, ISSN 0140-6736, 2009, Volume 374, Issue 9700, pp. 1503 - 1511
Summary Background Glatiramer acetate, approved for the treatment of relapsing-remitting multiple sclerosis, reduces relapses and disease activity and burden... 
Internal Medicine | MULTICENTER | THERAPY | AXONAL DAMAGE | MRI | RATIONALE | INFLAMMATION | GUIDELINES | DISABILITY | DIAGNOSTIC-CRITERIA | INTERFERON BETA-1A | MEDICINE, GENERAL & INTERNAL | Double-Blind Method | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Kaplan-Meier Estimate | Proportional Ha